Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

doi:10.2807/1560-7917.ES.2020.25.24.2001031

. 2020 Jun;25(24):2001031.

doi: 10.2807/1560-7917.ES.2020.25.24.2001031.

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

Elena Percivalle¹, Giuseppe Cambiè², Irene Cassaniti^{1

3}, Edoardo Vecchio Nepita^{1

3}, Roberta Maserati¹, Alessandro Ferrari^{1

3}, Raffaella Di Martino^{1

3}, Paola Isernia⁴, Francesco Mojoli^{3

5}, Raffaele Bruno^{3

6}, Marcello Tirani^{7

8}, Danilo Cereda⁸, Carlo Nicora⁹, Massimo Lombardo¹⁰, Fausto Baldanti^{1

3}

Affiliations

¹ Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, Pavia, Italy.
² Immunohematology and Transfusion Medicine Unit, Ospedale Maggiore di Lodi, Lodi, Italy.
³ Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
⁴ SIMT, Centro Lavorazione e Validazione, IRCCS Policlinico San Matteo, Pavia, Italy.
⁵ ICU1 Department of Intensive Medicine, IRCCS Policlinico San Matteo, Pavia, Italy.
⁶ Infectious Diseases I, Department of Medical Sciences and Infectious Diseases, IRCCS Policlinico San Matteo, Pavia, Italy.
⁷ Health Protection Agency of Pavia, Department of Hygiene and Preventive Medicine, Pavia, Italy.
⁸ Lombardy Region, Directorate General for Health, UO Prevenzione, Milan, Italy.
⁹ Chief Executive Office, IRCCS Policlinico San Matteo, Pavia, Italy.
¹⁰ Chief Executive Office, ASST Lodi, Lodi, Italy.

PMID: 32583766
PMCID: PMC7315724
DOI: 10.2807/1560-7917.ES.2020.25.24.2001031

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

Elena Percivalle et al. Euro Surveill. 2020 Jun.

. 2020 Jun;25(24):2001031.

doi: 10.2807/1560-7917.ES.2020.25.24.2001031.

Authors

Affiliations

¹ Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, Pavia, Italy.
² Immunohematology and Transfusion Medicine Unit, Ospedale Maggiore di Lodi, Lodi, Italy.
³ Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
⁴ SIMT, Centro Lavorazione e Validazione, IRCCS Policlinico San Matteo, Pavia, Italy.
⁵ ICU1 Department of Intensive Medicine, IRCCS Policlinico San Matteo, Pavia, Italy.
⁶ Infectious Diseases I, Department of Medical Sciences and Infectious Diseases, IRCCS Policlinico San Matteo, Pavia, Italy.
⁷ Health Protection Agency of Pavia, Department of Hygiene and Preventive Medicine, Pavia, Italy.
⁸ Lombardy Region, Directorate General for Health, UO Prevenzione, Milan, Italy.
⁹ Chief Executive Office, IRCCS Policlinico San Matteo, Pavia, Italy.
¹⁰ Chief Executive Office, ASST Lodi, Lodi, Italy.

PMID: 32583766
PMCID: PMC7315724
DOI: 10.2807/1560-7917.ES.2020.25.24.2001031

Erratum in

Author's correction for Euro Surveill. 2020;25(24).
Eurosurveillance editorial team. Eurosurveillance editorial team. Euro Surveill. 2022 Jan;27(3):220120c1. doi: 10.2807/1560-7917.ES.2022.27.3.220120c1. Euro Surveill. 2022. PMID: 35057897 Free PMC article. No abstract available.

Abstract

We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 - when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19-70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.

Keywords: Lodi Red Zone; SARS-CoV-2 seroprevalence; epidemiology; microneutralization assay.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

**Figure 1**
Distribution of blood donors in the 10 municipalities of the Lodi Red Zone, including those recruited for the study and those testing positive for SARS-CoV-2 neutralising antibodies, Lombardy, Italy, 18 March–6 April 2020 (n = 2,272 blood donors)

**Figure 2**
Distribution of NT-Abs titres in convalescent patients and blood donors, Italy, 2011–2020 (n = 129 individuals)

See this image and copyright information in PMC

Comment in

Letter to the editor: COVID-19: how accurate are seroprevalence studies?
Kadkhoda K. Kadkhoda K. Euro Surveill. 2020 Jul;25(30):2001374. doi: 10.2807/1560-7917.ES.2020.25.30.2001374. Euro Surveill. 2020. PMID: 32734860 Free PMC article. No abstract available.

Cited by

Ecologic association between influenza and COVID-19 mortality rates in European countries.
Petti S, Cowling BJ. Petti S, et al. Epidemiol Infect. 2020 Sep 11;148:e209. doi: 10.1017/S0950268820002125. Epidemiol Infect. 2020. PMID: 32912363 Free PMC article.
Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors.
Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, Gaggioli G, Giacobbe DR, Bracci-Laudiero L, Magnasco L, Signori A, Taramasso L, Varelli M, Vendola N, Ball L, Robba C, Battaglini D, Brunetti I, Pelosi P, Bassetti M. Vena A, et al. J Clin Med. 2020 Aug 27;9(9):2780. doi: 10.3390/jcm9092780. J Clin Med. 2020. PMID: 32867328 Free PMC article.
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report.
Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, Moutsatsou P, Scorilas A, Sphicopoulos T, Terpos E, Thomaidis N, Tsakris A, Voulgaris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostaki EG, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Trougakos IP, Tsiodras S, Sfikakis PP, Dimopoulos MA. Tsitsilonis OE, et al. Life (Basel). 2020 Sep 21;10(9):214. doi: 10.3390/life10090214. Life (Basel). 2020. PMID: 32967110 Free PMC article.
Circulation of SARS-CoV-2 Variants among Children from November 2020 to January 2022 in Trieste (Italy).
Dolci M, Signorini L, Cason C, Campisciano G, Kunderfranco P, Pariani E, Galli C, Petix V, Ferrante P, Delbue S, Comar M. Dolci M, et al. Microorganisms. 2022 Mar 14;10(3):612. doi: 10.3390/microorganisms10030612. Microorganisms. 2022. PMID: 35336187 Free PMC article.
Role of the 1^st booster dose of COVID-19 vaccine in the protection against the infection: A fundamental public health tool.
Calimeri S, Lo Giudice D, Buda A, Laganà A, Facciolà A, DI Pietro A, Visalli G. Calimeri S, et al. J Prev Med Hyg. 2022 Dec 31;63(4):E520-E526. doi: 10.15167/2421-4248/jpmh2022.63.4.2742. eCollection 2022 Dec. J Prev Med Hyg. 2022. PMID: 36891000 Free PMC article.

See all "Cited by" articles

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
1. World Health Organization (WHO). Novel coronavirus – China. Geneva: WHO; 12 Jan 2020. [Accessed 19 Jan 2020]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
1. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. 10.1001/jama.2020.4344 - DOI - PubMed
1. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. 10.1002/jmv.25882 - DOI - PMC - PubMed
1. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-65. 10.1172/JCI138745 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed

[2] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed

[3] World Health Organization (WHO). Novel coronavirus – China. Geneva: WHO; 12 Jan 2020. [Accessed 19 Jan 2020]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/

[4] World Health Organization (WHO). Novel coronavirus – China. Geneva: WHO; 12 Jan 2020. [Accessed 19 Jan 2020]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/

[5] Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. 10.1001/jama.2020.4344 - DOI - PubMed

[6] Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. 10.1001/jama.2020.4344 - DOI - PubMed

[7] Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. 10.1002/jmv.25882 - DOI - PMC - PubMed

[8] Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. 10.1002/jmv.25882 - DOI - PMC - PubMed

[9] Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-65. 10.1172/JCI138745 - DOI - PMC - PubMed

[10] Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-65. 10.1172/JCI138745 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

Affiliations

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous